Abbott’s Investigational SIMCOR® Offers Comparable LDL Lowering To Simvastatin And Significantly Raises HDL And Lowers Triglycerides In Phase III

New data released showed that Abbott’s SIMCOR®, an investigational, fixed-dose combination of Abbott’s proprietary extended-release niacin, Niaspan®, and simvastatin met its primary endpoint of lowering plaque-promoting non-HDL cholesterol (total cholesterol minus HDL), while demonstrating improvements on other key lipids, LDL “bad” cholesterol, HDL “good” cholesterol and triglycerides. [click link for full article]

More: continued here

Filed under: Cholesterol on November 6th, 2007